MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Bupivacaine Hydrochloride 250 mg/250 mL, Sufentanil 0.4 mg/250 mL Intravenous Injection (Solution, 250 mL)	FIN	F 004 775v2

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Bupivacaine Hydrochloride 0.5% Injection (Sterile), USP	50.00	mL				
Sufentanil 50 µg/mL Injection (Sterile), USP*	8.00	mL				
Sodium Chloride 0.9% for Injection, (Sterile), USP	192.0	mL				

*Delivered as Sufentanil Citrate.

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Controlled Substance *(adhere to proper handling and documentation procedures)* — *Sufentanil Citrate*

Light Sensitive *(protect from light whenever possible):* — *Sufentanil Citrate, Bupivacaine Hydrochloride*

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Bupivacaine Hydrochloride 250 mg/250 mL, Sufentanil 0.4 mg/250 mL Intravenous Injection (Solution, 250 mL)	FIN	F 004 775v2

SPECIAL PREPARATORY CONSIDERATIONS (CONTINUED)

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **3 to 5%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797* and *USP 800,* when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Compounder needs to verify as per USP, if every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

All required personal protective equipment (sterile and hazardous if applicable), such as but not limited to, gowns, aprons, sleeves, gloves both inner and outer if applicable, shoe covers, hairnet, head cap, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Bupivacaine Hydrochloride 250 mg/250 mL, Sufentanil 0.4 mg/250 mL Intravenous Injection (Solution, 250 mL)	FIN	F 004 775v2

SUGGESTED PREPARATION (for 250 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ___	Processing Error	Qty. to measure
Bupivacaine Hydrochloride 0.5% Injection (Sterile), USP §	50.00	mL			
Sufentanil 50 µg/mL Injection (Sterile), USP §	8.00	mL			
Sodium Chloride 0.9% for Injection, (Sterile), USP §	192.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

Preparatory Instruction **IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique**	
1.	**Equipment sterilization:** Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.
2.	**Medium integration:** **Note**: All manipulations must be done under a laminar airflow hood. Disinfect the commercial vials with Alcohol 70% prior to withdrawing the required amount of liquid. A. In the given order, sequentially add the following ingredients to the Sodium Chloride 0.9% for Injection (Sterile): -Bupivacaine Hydrochloride 0.5% Injection (Sterile) -Sufentanil 50 µg/mL Injection (Sterile) Specifications: Continuously mix. End result: Homogeneous liquid-like solution. Note: Add the next ingredient, once the previous one has been completely added and dispersed.
3.	**Filtering and transferring:** Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Bupivacaine Hydrochloride 250 mg/250 mL, Sufentanil 0.4 mg/250 mL Intravenous Injection (Solution, 250 mL)	FIN	F 004 775v2

4.	**Filter integrity test:** Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
5.	**Terminal Sterilization:** In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specifications.
6.	**Sterility and Endotoxin testing:** Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Bupivacaine Hydrochloride 250 mg/250 mL, Sufentanil 0.4 mg/250 mL Intravenous Injection (Solution, 250 mL)	FIN	F 004 775v2

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		48 hours controlled room temperature, 14 days refrigerated, or 45 days frozen, as per USP 797. BUD based on successful endotoxin test result.	Packaging Requirements		Sterile, tightly closed, light-resistant unit-dose injection vials.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	8		May impair mental and/or physical ability. Use care when operating a car or machinery.
	2	Keep out of reach of children.	9		Protect from light.
	3	Equilibrate to room temperature before use.	10		Keep at controlled room temperature, (20°C – 25°C), refrigerated (2°C – 8°C) or frozen (-25°C to -10°C).
	4	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.	11		May produce psychological and/or physical dependence.
	5	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	12		Controlled substance. Dangerous unless used as directed.
	6	**For medical office use only.**	13		Discard in the presence of particulate matter.
	7	Do not used if discolored.			
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. **IMPORTANT: TO BE ADMINISTERED ONLY BY THE PRESCRIBING PHYSICIAN.**				
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

Suggested Formula	Bupivacaine Hydrochloride 250 mg/250 mL, Sufentanil 0.4 mg/250 mL Intravenous Injection (Solution, 250 mL)	FIN	F 004 775v2

REFERENCES

1. Parenteral Preparations. In: Allen, LV, Jr. *The Art, Science and Technology of Pharmaceutical Compounding Third Edition.* American Pharmaceutical Association; 2008: 313.
2. Bupivacaine Hydrochloride. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 36th Edition.* London, England: The Pharmaceutical Press; 2009: 1854.
3. Sufentanil Citrate. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 36th Edition.* London, England: The Pharmaceutical Press; 2009: 125.
4. Bupivacaine (Monograph). In: O'Neil MJ. *The Merck Index 14th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #1495.
5. Sufentanil (Monograph). In: O'Neil MJ. *The Merck Index 14th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #8887.
6. Bupivacaine Hydrochloride. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 3rd Edition.* American Pharmaceutical Association; 2005: 59.
7. Bupivacaine Hydrochloride. *United States Pharmacopeia XXXII / National Formulary 27.* Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 1718.
8. Sufentanil Citrate (Monograph). *United States Pharmacopeia XXXIV / National Formulary 29.* Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 4284.
9. USP <797>. United States Pharmacopeia XXXII / National Formulary 27. Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 318.